Skip to main content
News

Rusfertide Significantly Improves Hematocrit Control and Reduces Phlebotomy Burden in Polycythemia Vera

Edited by 

Clinical Summary:

  • Design/Population: The VERIFY trial evaluated rusfertide, a subcutaneous hepcidin mimetic, in patients with phlebotomy-dependent polycythemia vera and poorly controlled hematocrit receiving standard-of-care treatment with or without cytoreductive therapy. 
  • Key Outcomes: Rusfertide significantly improved clinical response, reduced the mean number of phlebotomies, and increased the proportion of patients maintaining hematocrit below 45%. Significant improvements in patient-reported fatigue and overall symptom burden were also observed. 
  • Clinical Relevance: These findings support rusfertide as a potential treatment option for patients who require frequent phlebotomy and highlight the need for longer-term evaluation of thrombotic and disease-related outcomes. 

Results from the phase 3 VERIFY trial demonstrated that rusfertide significantly improved hematocrit control, reduced therapeutic phlebotomy requirements, and improved patient-reported symptoms in patients with phlebotomy-dependent polycythemia vera receiving standard treatment, supporting the hepcidin mimetic as a potential new treatment option. 

“Polycythemia vera is a chronic myeloproliferative neoplasm characterized by prominent clonal panmyelosis and marked erythrocytosis that elevates hematocrit, leading to an increased risk of thrombosis,” stated Andrew Kuykendall, MD, Moffitt Cancer Center, Tampa, Florida, and coauthors. “Rusfertide is a subcutaneous, injectable, hepcidin mimetic peptide that suppresses erythrocytosis.” 

In this double-blind, placebo-controlled trial, 293 patients were randomized 1:1 to receive either subcutaneous rusfertide (n = 147) or placebo (n = 146) once weekly in addition to standard-of-care treatment. Patients were required to have undergone at least 3 phlebotomies within 28 weeks or at least 5 phlebotomies within 1 year before randomization. Rusfertide dosing was individualized to achieve and maintain hematocrit below 45%. 

The primary end point was clinical response during weeks 20 to 32, defined as the absence of phlebotomy eligibility and specified intercurrent events. Key secondary end points included the mean number of phlebotomies, maintenance of hematocrit below 45%, and changes in patient-reported fatigue and symptom burden through week 32.

During the randomized treatment period, 77% of patients receiving rusfertide achieved a clinical response compared with 33% of patients receiving placebo (P < .0001). The mean number of phlebotomies during the 32-week treatment period was significantly lower with rusfertide than placebo (0.5 vs 1.8; P < .0001). 

Overall, 73% of patients receiving rusfertide remained phlebotomy-free compared with 22% of patients receiving placebo. A significantly greater proportion of patients receiving rusfertide maintained hematocrit below 45% compared with placebo (63% vs 14%; P < .0001). 

These benefits were generally consistent across prespecified subgroups, including patients receiving phlebotomy alone and those receiving concomitant cytoreductive therapy.

Rusfertide also significantly improved patient-reported fatigue and symptom burden. At week 32, the mean change from baseline in the Patient-Reported Outcomes Measurement Information System (PROMIS) Fatigue Short Form 8a T-score was −3.9 with rusfertide compared with −1.1 with placebo (P = .0252). Similarly, the mean change in the Myelofibrosis Symptom Assessment Form Total Symptom Score-7 was −3 with rusfertide compared with −0.1 with placebo (P = .0240).

The improvements in hematocrit control and reduced phlebotomy requirements were sustained during the open-label extension period.  

Among patients initially assigned to rusfertide who achieved the primary end point during weeks 20 to 32, 84% of patients maintained their response during weeks 32 to 52. Among patients initially assigned to placebo who switched to rusfertide at week 32, 78% of patients achieved a clinical response during weeks 40 to 52.

The safety profile of rusfertide was generally consistent with prior findings, with injection-site reactions, anemia, and fatigue representing the most common adverse events. 

During the double-blind period, grade 3 adverse events occurred in 9% of patients in the rusfertide arm and 7% of patients in the placebo arm. Serious adverse events occurred in 3% and 5% of patients, respectively. 

Injection-site reactions occurred in 56% of patients receiving rusfertide and 33% of patients receiving placebo. No deaths were reported during the study.

Results demonstrated that “rusfertide with current standard-of-care therapy provided rapid, consistent, and durable hematocrit control <45% in the absence of increased phlebotomy or cytoreductive therapy burden,” concluded Dr Kuykendall et al. “Ongoing longer-term follow-up in VERIFY and the phase 2 THRIVE extension study will further characterize these outcomes.”


Source:

Kuykendall AT, Bankar A, Pettit KM, et al. VERIFY: A phase III trial of rusfertide versus placebo in phlebotomy-dependent patients with polycythemia vera receiving standard-of-care therapy. J Clin Oncol. Published online: October 13, 2026. doi: 10.1200/jco-26-00992

© 2026 HMP Global. All Rights Reserved.
Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of LL&M, Oncology Learning Network or HMP Global, their employees, and affiliates.